Imunon Q3 net loss $3.5M; OVATION 2 shows 33% PFS improvement, OS benefit

Imunon, Inc.

2023-Q3 EPS reported -$1.64

Net loss of $3.5M ($0.37 per share) vs $6.1M loss in Q3 2022; operating expenses down 38% to $3.9M.
Cash and equivalents $19.5M as of Sept 30, 2023; expects $1.8M from NJ NOL sales.
Interim OVATION 2 data: PFS improved ~33% in treatment arm; OS improved ~9 months; median PFS 23.7 months with PARP inhibitor combo vs 15.7 months control.
Enrolled first patient in Phase 1/2 trial of IMNN-001 + bevacizumab at MD Anderson; IND filing for IMNN-101 COVID booster on track for Q1 2024.
Entered CRADA with NIAID for Lassa virus vaccine evaluation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Imunon, Inc. reported financial results for the three and nine months ended September 30, 2023.

Period: the three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, Imunon, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.